Consensus Clearside Biomedical, Inc.

Equities

CLSD

US1850631045

Market Closed - Nasdaq 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
1.53 USD -8.38% Intraday chart for Clearside Biomedical, Inc. -15.00% +30.77%

Evolution of the average Target Price on Clearside Biomedical, Inc.

Price target over the last 5 years

History of analyst recommendation changes

66cf1257788ae9c.LtFfXhaRxoU5JKcnLfKzb0_97gQIrSGRkWVVehA3pgI.RpIYZy_Vl9peRpRSXprXBjjQrVI5lHTo6zovOV0O0W5M_DsEJOKi81Rvkw~c138b7df969bd9016f344e3bb3ccd0e3
Wedbush Trims Clearside Biomedical's PT to $4 From $5 After Increased Share Count, Model Adjustments; Maintains Outperform Rating MT
JonesTrading Intiates Coverage on Clearside Biomedical With Buy Rating, $6 Price Target MT
Needham Adjusts Price Target on Clearside Biomedical to $4 From $5, Maintains Buy Rating MT
JMP Securities Adjusts Clearside Biomedical Price Target to $6 From $7, Maintains Market Outperform Rating MT
Wedbush Lifts Clearside Biomedical's Price Target to $5 From $4 After Model Adjustments, Keeps Outperform Rating MT
Wedbush Adjusts Clearside Biomedical's Price Target to $4 From $6, Keeps Outperform Rating MT
Wedbush Adjusts Clearside Biomedical Price Target to $4 From $6, Maintains Outperform Rating MT
Needham Upgrades Clearside Biomedical to Buy Rating From Hold, Price Target is $5 MT
Stifel Upgrades Clearside Biomedical to Buy From Hold, Price Target is $8 MT
Wedbush Lowers Clearside Biomedical's Price Target to $6 From $9, Keeps Outperform Rating MT
HC Wainwright Adjusts Clearside Biomedical's Price Target to $5 from $10, Keeps Buy Rating MT
Wedbush Removes Outperform-Rated Clearside Biomedical From Best Ideas List; Price Target is $9 MT
Wedbush Adds Outperform-Rated Clearside Biomedical to Best Ideas List, Citing 'Potentially Transformative Dual Approach' for wAMD Treatment, Adjusts PT to $9 From $19 on Peak Sale Estimates MT
Roth Capital Adjusts Clearside Biomedical's Price Target to $17 From $15, Reiterates Buy Rating MT
CLEARSIDE BIOMEDICAL : Wedbush Lifts Price Target for Clearside Biomedical to $19 From $18, Maintains Outperform Rating MT
CLEARSIDE BIOMEDICAL : HC Wainwright Starts Clearside Biomedical at Buy With $10 Price Target MT
CLEARSIDE BIOMEDICAL : Roth Capital Adjusts Price Target on Clearside Biomedical to $15 From $9, Maintains Buy Rating MT
CLEARSIDE BIOMEDICAL : Wedbush Adjusts PT on Clearside Biomedical to $18 From $6 on CLS-AX Potential in Treating Wet Age-Related Macular Degeneration; Outperform Rating Kept MT
CLEARSIDE BIOMEDICAL : Stifel Adjusts Clearside Biomedical's Price Target to $5 From $3.50, Maintains Hold Rating MT
CLEARSIDE BIOMEDICAL : JMP Securities Adjusts Clearside Biomedical PT to $9 From $8, Maintains Market Outperform Rating MT
CLEARSIDE BIOMEDICAL : Roth Capital Adjusts Clearside Biomedical PT to $9 From $8, Maintains Buy Rating MT
CLEARSIDE BIOMEDICAL : Wedbush Adjusts Price Target on Clearside Biomedical to $6 From $5, Keeps Outperform Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
1.53 USD
Average target price
5.4 USD
Spread / Average Target
+252.94%
High Price Target
8 USD
Spread / Highest target
+422.88%
Low Price Target
4 USD
Spread / Lowest Target
+161.44%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Clearside Biomedical, Inc.

Wedbush
JonesTrading Institutional Services
JMP Securities
Needham & Co.
Stifel Nicolaus
HC Wainwright
Roth Capital Partners
Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings